Evidence map›Paper›PMID 41601722›Full record

ArticleFrontiers in medicine2025

Safety profile of vunakizumab in elderly patients with moderate-to-severe plaque psoriasis: a

Tong Mu, Yuanxiong He, Min Zhang, Chunyou Wang, Zhifang Zhai, Zhiqiang Song

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04839016 (A Randomized, Double-blind, Multicenter, Placebo-controlled, Phase III Adaptive Study of SHR-1314 to Assess Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04839016 phase3unknown statusnot on this map

A Randomized, Double-blind, Multicenter, Placebo-controlled, Phase III Adaptive Study of SHR-1314 to Assess Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis

TypeinterventionalSponsorJiangsu HengRui Medicine Co., Ltd.Ran2021 to 2023Enrolled660ConditionsModerate-to-Severe Plaque PsoriasisArmsSHR-1314, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tong Mu *Department of Dermatology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China.
Yuanxiong He *Department of Dermatology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China.
Min ZhangDepartment of Dermatology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China.
Chunyou WangDepartment of Dermatology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China.
Zhifang ZhaiDepartment of Dermatology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China.
Zhiqiang SongDepartment of Dermatology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Elderly patients with moderate-to-severe plaque psoriasis are vulnerable to adverse events (AEs), which raise safety concerns in their management. This Methods: Data were extracted from a phase III trial (NCT04839016). A total of 70 elderly patients with moderate-to-severe plaque psoriasis were included and assigned to the vunakizumab ( Results: During the induction period, the incidence of any AEs (63.3% vs. 76.2%) ( Conclusion: Vunakizumab is safe and effective in elderly patients with moderate-to-severe plaque psoriasis.

Indexed as

efficacyelderly patientsmoderate-to-severe plaque psoriasissafetyvunakizumab

Identifiers

PMID41601722
PMCPMC12832387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.